Suppr超能文献

实验性利什曼病中的巨噬细胞特异性药物递送

Macrophage specific drug delivery in experimental leishmaniasis.

作者信息

Basu Mukul Kumar, Lala Sanchaita

机构信息

Indian Institute of Chemical Biology, 4, Raja SC Mullick Road, Kolkata-700032, India.

出版信息

Curr Mol Med. 2004 Sep;4(6):681-9. doi: 10.2174/1566524043360186.

Abstract

Macrophage-specific delivery systems are the subject of much interest nowadays, because of the fact that macrophages act as host cells for many parasites and bacteria, which give rise to outbreak of so many deadly diseases(eg. leishmaniasis, tuberculosis etc.) in humans. To combat these deadly diseases initially macrophage specific liposomal delivery system were thought of and tested in vivo against experimental leishmaniasis in hamsters using a series of indigenous or synthetic antileishmanial compounds and the results were critically discussed. In vitro testing was also done against macrophages infected with Leishmania donovani, the causative agent for visceral leishmaniasis. The common problem of liposome therapy being their larger size, stability and storage, non-ionic surfactant vesicles, niosomes were prepared, for their different drug distribution and release characteristics compared to liposomes. When tested in vivo, the retention capacity of niosomes was found to be higher than that of liposomes due to the absence of lipid molecules and their smaller size. Thus the therapeutic efficacy of certain antileishmanial compounds was found to be better than that in the liposomal form. The niosomes, being cheaper, less toxic, biodegradable and non-immunogenic, were considered for sometime as suitable alternatives to liposomes as drug carriers. Besides the advent of other classical drugs carriers(e.g. neoglycoproteins), the biggest challenge came from polymeric delivery vehicles, specially the polymeric nanoparticles which were made of cost effective biodegradable polymers and different natural polymers. Because of very small size and highly stable nature, use of nanoparticles as effective drug carriers has been explored in experimental leishmaniasis using a series of antileishmanial compounds, both of indigenous and synthetic origin. The feasibility of application in vivo, when tested for biological as well as for other physicochemical parameters, the polymeric nanoparticles have turned out to be the best and thus may be projected for effective use in the clinics.

摘要

巨噬细胞特异性递送系统是当下备受关注的课题,因为巨噬细胞是许多寄生虫和细菌的宿主细胞,这些寄生虫和细菌会引发人类众多致命疾病(如利什曼病、结核病等)的爆发。为了对抗这些致命疾病,最初人们设想并在体内对巨噬细胞特异性脂质体递送系统进行了测试,使用一系列本土或合成的抗利什曼病化合物来对抗仓鼠实验性利什曼病,并对结果进行了批判性讨论。还针对感染内脏利什曼病病原体杜氏利什曼原虫的巨噬细胞进行了体外测试。脂质体疗法的常见问题在于其尺寸较大、稳定性和储存性不佳,因此制备了非离子表面活性剂囊泡(脂质体),因其与脂质体相比具有不同的药物分布和释放特性。在体内测试时,由于不存在脂质分子且尺寸较小,脂质体的保留能力被发现高于脂质体。因此,某些抗利什曼病化合物的治疗效果被发现比脂质体形式更好。脂质体由于价格便宜、毒性较小、可生物降解且无免疫原性,在一段时间内被视为脂质体作为药物载体的合适替代品。除了其他经典药物载体(如新糖蛋白)的出现,最大的挑战来自聚合物递送载体,特别是由具有成本效益的可生物降解聚合物和不同天然聚合物制成的聚合物纳米颗粒。由于尺寸非常小且性质高度稳定,在实验性利什曼病中使用一系列本土和合成来源的抗利什曼病化合物探索了将纳米颗粒用作有效药物载体的可行性。在对生物以及其他物理化学参数进行体内测试时,聚合物纳米颗粒已被证明是最佳的,因此有望在临床上有效使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验